Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart reflex test may forecast AFib ablation success

NCT ID NCT04503122

Knowledge-focused Sponsor: Poitiers University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 116 people with paroxysmal atrial fibrillation (AFib) who were scheduled for a heart ablation procedure. Researchers measured baroreflex sensitivity—a non-invasive test of the autonomic nervous system—before the procedure. They wanted to see if this measurement could predict whether AFib would come back within a year. The goal is to better understand why AFib returns and to help select patients who are most likely to benefit from ablation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict who will benefit most from atrial fibrillation ablation, reducing recurrence rates.
What could go wrong
This is an observational study, not a treatment trial. The results may not lead to immediate changes in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

116 people

The number who actually took part.

Started

Jun 2021

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with paroxysmal atrial fibrillation undergoing atrial fibrillation ablation

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old, * Patients with paroxysmal atrial fibrillation, hospitalized for atrial fibrillation ablation, * Assessable baroreflex sensitivity before ablation, * Free subject, without guardianship or curatorship or subordination, * Patients benefiting from a Social Security assurance, * Informed consent signed by the patient after clear and fair information about the study. Exclusion Criteria: * Age \< 18, * History of atrial fibrillation ablation, * Inability to calculate the baroreflex sensitivity * Contraindication to the performance of a cardiac CT scan (allergy to iodine, severe renal insufficiency with clearance \<30 ml/mn/m2), * Inability to have continuous ECG recording by subcutaneous Holter,

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Paroxysmal atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation paroxysmal atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Paroxysmal atrial fibrillation

Contacts and locations

Locations

  • CHU de Poitiers

    Poitiers, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.